[
    [
        {
            "time": "2020-07-20",
            "original_text": "上海医药(02607)将于7月20日派发A股每股现金红利0.44元",
            "features": {
                "keywords": [
                    "上海医药",
                    "派发",
                    "现金红利",
                    "A股"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "上海医药(02607)将于7月20日派发A股每股现金红利0.44元",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020",
            "original_text": "两家中国企业上榜！强生、罗氏、拜耳凭什么稳居前三？2020全球最具价值医药企业品牌TOP25发布",
            "features": {
                "keywords": [
                    "中国企业",
                    "强生",
                    "罗氏",
                    "拜耳",
                    "医药企业",
                    "品牌"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "两家中国企业上榜！强生、罗氏、拜耳凭什么稳居前三？2020全球最具价值医药企业品牌TOP25发布",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 3,
                "Duration": 3,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 4
            }
        },
        {
            "time": "2020",
            "original_text": "上海医药(02607.HK)A股每股拟派红利0.44元(含税)",
            "features": {
                "keywords": [
                    "上海医药",
                    "拟派",
                    "红利",
                    "A股"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "上海医药(02607.HK)A股每股拟派红利0.44元(含税)",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-07-17",
            "original_text": "上海医药(601607.SH)2019年度A股权益分派10派4.4元股权登记日为7月17日",
            "features": {
                "keywords": [
                    "上海医药",
                    "权益分派",
                    "股权登记日"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "上海医药(601607.SH)2019年度A股权益分派10派4.4元股权登记日为7月17日",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-07-09",
            "original_text": "格隆汇个股放量排行榜|7月9日",
            "features": {
                "keywords": [
                    "格隆汇",
                    "个股",
                    "放量",
                    "排行榜"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "格隆汇个股放量排行榜|7月9日",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 2,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2020",
            "original_text": "被纳入优先审评的10款重磅药物 达格列净片、维奈克拉片",
            "features": {
                "keywords": [
                    "优先审评",
                    "重磅药物",
                    "达格列净片",
                    "维奈克拉片"
                ],
                "sentiment_score": 0.75,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "被纳入优先审评的10款重磅药物 达格列净片、维奈克拉片",
                "Correlation": 5,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020",
            "original_text": "CBRE世邦魏理仕：2020年上半年上海房地产市场回顾与展望",
            "features": {
                "keywords": [
                    "CBRE",
                    "世邦魏理仕",
                    "房地产",
                    "上海",
                    "回顾与展望"
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "房地产"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "CBRE世邦魏理仕：2020年上半年上海房地产市场回顾与展望",
                "Correlation": 1,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 2,
                "Duration": 5,
                "Entity_Density": 1,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "2020",
            "original_text": "2020全球最有价值制药品牌TOP25",
            "features": {
                "keywords": [
                    "全球",
                    "制药品牌",
                    "TOP25"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "2020全球最有价值制药品牌TOP25",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "2020",
            "original_text": "从“兵家必争之地”到“烫手山芋” 多家药企剥离药房",
            "features": {
                "keywords": [
                    "药企",
                    "剥离",
                    "药房"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "从“兵家必争之地”到“烫手山芋” 多家药企剥离药房",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020",
            "original_text": "“监管常客”紫鑫药业陷恶性循环，存货应收双高，债务逾期超过11亿 运营能力下降",
            "features": {
                "keywords": [
                    "紫鑫药业",
                    "监管",
                    "恶性循环",
                    "债务逾期",
                    "运营能力下降"
                ],
                "sentiment_score": 0.2,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "“监管常客”紫鑫药业陷恶性循环，存货应收双高，债务逾期超过11亿 运营能力下降",
                "Correlation": 8,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]